Trials / Completed
CompletedNCT00679133
Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.
Detailed description
MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase inhibitors. MGCD265 was shown to slow down the growth of human cancer cells in mice. Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients. In this study, oral MGCD265 is administered daily on a 7 days on / 7 days off schedule to patients with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGCD265 | Oral daily administration; 7 days on / 7 days off |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2008-05-16
- Last updated
- 2015-01-08
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00679133. Inclusion in this directory is not an endorsement.